A multicenter randomized trial of Fludarabine and Mitoxantrone (FM) plus Rituximab versus CHOP plus Rituximab as first-line treatment in patients with follicular lymphoma (FL).

被引：0
|
作者：
Zinzani, PL [1 ]
机构：
[1] Univ Bologna, Inst Hematol & Med Oncol L & A Seranoli, I-40126 Bologna, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
344
引用
收藏
页码：93A / 93A
页数：1
相关论文
共 50 条
  • [41] Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients
    Foa, Robin
    Del Giudice, Ilaria
    Cuneo, Antonio
    Del Poeta, Giovanni
    Ciolli, Stefania
    Di Raimondo, Francesco
    Lauria, Francesco
    Cencini, Emanuele
    Rigolin, Gian Matteo
    Cortelezzi, Agostino
    Nobile, Francesco
    Callea, Vincenzo
    Brugiatelli, Maura
    Massaia, Massimo
    Molica, Stefano
    Trentin, Livio
    Rizzi, Rita
    Specchia, Giorgina
    Di Serio, Francesca
    Orsucci, Lorella
    Ambrosetti, Achille
    Montillo, Marco
    Zinzani, Pier Luigi
    Ferrara, Felicetto
    Morabito, Fortunato
    Mura, Maria Angela
    Soriani, Silvia
    Peragine, Nadia
    Tavolaro, Simona
    Bonina, Silvia
    Marinelli, Marilisa
    De Propris, Maria Stefania
    Della Starza, Irene
    Piciocchi, Alfonso
    Alietti, Alessandra
    Runggaldier, Eva Josephine
    Gamba, Enrica
    Mauro, Francesca Romana
    Chiaretti, Sabina
    Guarini, Anna
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (05) : 480 - 486
  • [42] Re-treatment with rituximab plus chemotherapy in patients with aggressive lymphoma treated previously with CHOP or CHOP-like combinations plus rituximab.
    Palacios, Andres
    Navarrete, Mayda
    Gallur, Laura
    Zuazu, Javier
    Barrenetxea, Cristina
    Sanchez, Eva
    Lopez, Andres
    BLOOD, 2006, 108 (11) : 259B - 259B
  • [43] Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data
    Zinzani, Pier Luigi
    Topp, Max S.
    Yuen, Sam L. S.
    Rusconi, Chiara
    Fleury, Isabelle
    Pro, Barbara
    Gritti, Giuseppe
    Crump, Michael
    Hsu, Wanling
    Punnoose, Elizabeth A.
    Hilger, James
    Mobasher, Mehrdad
    Hiddermann, Wolfgang
    BLOOD, 2016, 128 (22)
  • [44] Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
    Zinzani, Pier Luigi
    Khuageva, Nuriet K.
    Wang, Huaqing
    Garicochea, Bernardo
    Walewski, Jan
    Van Hoof, Achiel
    Soubeyran, Pierre
    Caballero, Dolores
    Buckstein, Rena
    Esseltine, Dixie-Lee
    Theocharous, Panteli
    Enny, Christopher
    Zhu, Eugene
    Elsayed, Yusri A.
    Coiffier, Bertrand
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [45] Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma
    Hornberger, J.
    Reyes, C.
    Verhulst, E.
    Lubeck, D.
    Valente, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] PERSPECTIVE: A Randomized, Phase 3 Study of Ibrutinib-Rituximab Versus Placebo-Rituximab Combination Therapy for First-Line Treatment of Follicular Lymphoma
    Flinn, Ian
    Gordon, Leo
    Rule, Simon
    Chen, Robert
    Kwei, Long
    Chu, Alvina
    Fowler, Nathan
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S12 - S13
  • [47] Copanlisib plus rituximab versus rituximab plus placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.
    Matasar, Matthew J.
    Capra, Marcelo
    Ozcan, Muhit
    Lv, Fangfang
    Li, Wei
    Yanez, Eduardo
    Sapunarova, Katya
    Lin, Tongyu
    Jin, Jie
    Jurczak, Wojciech
    Hamed, Aryan
    Wang, Ming-Chung
    Soler, Lidia Mongay
    Cao, Anjun
    Phelps, Charles
    Childs, Barrett H.
    Shi, Yuankai
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Rituximab as first-line treatment of patients with follicular lymphoma (FL) and a low-burden tumor: Clinical and molecular evaluation.
    Solal-Celigny, P
    Salles, G
    Brousse, N
    Eftekhari, P
    Soubeyran, P
    Lacotte, L
    Deconinck, E
    Haioun, C
    Foussard, C
    Sebban, C
    Stamatoulas, A
    Milpied, N
    Boue, F
    Taillan, B
    Lederlin, P
    Najman, A
    Mathieu-Boue, A
    Benzohra, A
    Colombat, P
    BLOOD, 1999, 94 (10) : 631A - 631A
  • [49] Phase II study with Fludarabine and Cyclophosphamide plus Rituximab (FC plus R) in relapsed follicular lymphoma patients.
    Sacchi, S
    Tucci, A
    Merli, F
    Orsucci, L
    Cervetti, G
    Occhini, U
    Liberati, M
    Tarantini, G
    Callea, V
    Brugiatelli, M
    Lauta, VM
    Baldini, L
    Luminari, S
    Federico, M
    BLOOD, 2002, 100 (11) : 572A - 572A
  • [50] Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial
    Kahl, Brad S.
    Burke, John M.
    van der Jagt, Richard
    Chang, Julie
    Wood, Peter
    Hawkins, Tim
    MacDonald, David
    Trotman, Judith
    Simpson, David
    Kolibaba, Kathryn S.
    Issa, Samar
    Hallman, Doreen
    Chen, Ling
    Flinn, Ian W.
    BLOOD, 2017, 130
12345